Original article
Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: A systematic review with an indirect comparison meta-analysis

https://doi.org/10.1016/j.sjbs.2018.11.013Get rights and content
Under a Creative Commons license
open access

Abstract

To describe the effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid (SUA) in patients with type 2 diabetes mellitus (T2DM). PubMed, EMBASE, and CENTRAL were searched for randomized controlled trials of SGLT2 inhibitors in patients with T2DM up to Aug 10, 2017, without language or date restrictions. Thirty-one studies totaling 13,650 patients were included. SGLT2 inhibitors significantly decreased SUA levels compared with placebo, canagliflozin WMD –37.02 μmol/L, 95% CI [–38.41, –35.63], dapagliflozin WMD –38.05 μmol/L, 95% CI [–44.47, –31.62], empagliflozin WMD –42.07 μmol/L, 95% CI [–46.27, –37.86]. The drug class effect of SUA reduction suggesting SGLT2 inhibitors might be beneficial for diabetic patients with hyperuricemia.

Abbreviations

SGLT2
sodium-glucose co-transporter 2
RCTs
randomized controlled trials
CKD
chronic kidney disease
N
number of patients
CANA
canagliflozin
DAPA
dapagliflozin
EMPA
empagliflozin
PLA
placebo

Keywords

Meta-analysis
Serum uric acid
SGLT2 inhibitor
Type 2 diabetes

Cited by (0)

Peer review under responsibility of King Saud University.

1

These authors contributed equally to this work.